The past few years have seen major progress in cancer research and treatment. Today we are able to select treatments based on molecular profiling of tumors and do not solely rely on tumor type and stage. The most recent advance has taken place in the field of immunotherapy, and at this year’s ASCO again a huge number of studies were reported dealing with immunotherapy. In Europe we expect approval of different immunotherapies in various entities ranging from head and neck cancer, urothelial cancer, gastric cancer to lung cancer and colorectal cancer. But immunotherapy is not the only area of progress. There are tremendous advances in surgery, chemotherapy and targeted agents, too, as will be discussed in further detail in this report of the most important abstracts of this year’s ASCO by our experts in the field Drs. Wöll, Bartsch, Pall, Roider-Schur, Hamacher, Brodowicz, Kacirek, and myself.